紫杉醇联合顺铂新辅助化疗在非手术治疗局部晚期宫颈癌患者中的临床应用价值

目的分析紫杉醇联合顺铂新辅助化疗方案(NACT)在非手术治疗局部晚期宫颈癌患者中的临床应用价值。方法将我院收治的88例非手术治疗局部晚期宫颈癌患者按治疗方式分为对照组44例,单纯同步放化疗(CCRT)]与观察组(44例,NACT+CCRT),比较两组的临床疗效。结果观察组的近期有效率及两年内生存率高于对照组(P<0.05)。治疗后,观察组肿瘤直径小于对照组,肿瘤直径缩小率高于对照组(P<0.05)。治疗后,观察组的SCC-Ag、CEA、CA15-3、CYFRA21-1水平低于对照组(P<0.05)。结论针对非手术治疗局部晚期宫颈癌患者,采用紫杉醇联合顺铂NACT方案可提高近期疗效,促进肿瘤缩小,显著降低肿瘤标志物水平,且不增加副作用。

Clinical application value of paclitaxel combined with cisplatin neoadjuvant chemotherapy in non-surgical treatment of locally advanced cervical cancer

Objective To analyze the clinical application value of paclitaxel combined with cisplatin neoadjuvant chemotherapy(NACT)in non-surgical treatment of locally advanced cervical cancer.Methods A total of 88 patients with locally advanced cervical cancer treated by non-surgical treatment in our hospital were divided into control group44 cases,simple concurrent radiochemotherapy(CCRT)]and observation group(44 cases,NACT+CCRT)according to the treatment mode.The clinical efficacy of the two groups was compared.Results The short-term effective rate and two-year survival rate of the observation group were higher than those of the control group(P<0.05).After treatment,the tumor diameter of the observation group was smaller than that of the control group,and the tumor diameter reduction rate was higher than that of the control group(P<0.05).After treatment,the levels of SCC-AG,CEA,CA15-3 and CYFRA21-1 in the observation group were lower than those in the control group(P<0.05).Conclusion For the non-surgical treatment of locally advanced cervical cancer patients,paclitaxel combined with cisplatin NACT regimen can improve the short-term efficacy,promote tumor shrinkage,significantly reduce the levels of tumor markers,and do not increase side effects.